Dílčí analýzy studie DECLARE-TIMI 58 objasnily kardiovaskulární přínos dapagliflozinu u podskupin pacientů s diabetem 2. typu a také jeho renoprotektivní vliv

Abstract

Souhrn s komentářem. Citace: 1.

Firtado RHM, Bonaca MP, Raz I. et al. Dalagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction.

Circulation. 2019 May 28; 139(ěě): 2516-2527. doi: 10.1161/CIRCULATIONAHA. 119.03996. Epub 2019 Mar 18. 2.

Mosenzon O, Wiviot SDt, Cahn A. et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Lancet Diabetes Endocrinol 2019. Published Online June 9, 2019 http://dx. doi.org /10.1016 /S2213-8587(19)30180-9

Keywords

• dapagliglozin
• diabetes mellitus